> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review for BMS Lung Cancer Drug
- URL: https://www.fdaweb.com/priority-review-for-bms-lung-cancer-drug/
- Published: 2023-05-30T12:00:00.000Z
- Updated: 2026-09-14T18:35:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154566

FDA has accepted for priority review a Bristol Myers Squibb NDA for repotrectinib, a next-generation tyrosine kinase inhibitor (TKI) for treating patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The agency has set a review action target date of 11/27.

The submission is based on data from the company’s TRIDENT-1 study, which the company says “demonstrated high response rates and clinically meaningful durability of benefit in both TKI-naïve and TKI-pretreated patients, including those with ROS1 resistance mutations.” The study is ongoing to assess long-term outcomes and additional endpoints across patient populations with ROS1-positive locally advanced or metastatic NSCLC and NTRK-positive advanced solid tumors, it says. Repotrectinib’s safety profile is reported by the company as “well characterized and manageable.”